Prurigo nodularis
MONDO:0026045Prurigonodularis (PN) is a skin disease in which hard crusty lumps are formed on the skin that itches intensely. Repetitive rubbing, scratching, and touching results in more lesions in the skin. The itching is so intense that people scratch themselves to the point of bleeding or pain. The lumps formed in the skin are hard, and have about a half inch across, with a dry and rough top that is often scratched open. They tend to be located in the areas most easily reached and are worse on the outer sides: arms, shoulders and legs. The trunk, face and even palms can also be affected. The exact cause is unknown but some factors triggering PN include liver and kidneys problems, nervous and mental conditions and other skin diseases. Prurigo nodulares, in some cases, can be seen in other diseases such as lymphoma, chronic autoimmune cholestatic hepatitis, HIV infection, severe anemia,or a chronic kidney disease-related itching known as uremic pruritus. Treatment is very difficult, and may include corticoids, antihistaminic and other medication such as thalidomide and similar (Lenalidomide). In some cases, cryotherapy, photochemotherapy and habit reversal therapy for the itch-scratch cycle has improved the symptoms. PN can last for many years, and the itching is so intense that may affect all the everyday activities.
29 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Could dupixent help kids with chronic itchy skin disease?
Disease control Recruiting nowThis study tests the drug dupilumab (Dupixent) in 18 children aged 6 months to 18 years with prurigo nodularis, a condition causing very itchy skin bumps. The main goals are to measure how the drug moves through the body and to check for side effects. Participants receive injecti…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New study tracks Dupilumab's Long-Term impact on chronic itch condition
Disease control Recruiting nowThis study follows 40 adults with moderate-to-severe prurigo nodularis who are starting dupilumab (Dupixent). Researchers will track how well the drug controls itching and skin lesions over time, and also study changes in immune cells and proteins in the skin and blood. The goal …
Sponsor: UMC Utrecht • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
AI reads your skin: new tool aims to help doctors spot rashes and moles
Diagnosis Recruiting nowThis study is testing a software tool called Belle.ai that uses artificial intelligence to help doctors diagnose common skin diseases. About 400 patients at dermatology clinics will have three photos taken of their skin condition. The AI will analyze the photos and suggest possib…
Sponsor: Wake Forest University Health Sciences • Aim: Diagnosis
Last updated Jun 27, 2026 07:55 UTC
-
New Real-World study tests nemolizumab for chronic itch condition
Symptom relief Recruiting nowThis study looks at how well the drug nemolizumab works for adults with moderate-to-severe prurigo nodularis, a skin condition that causes intense itching and bumps. Researchers will track 600 participants over 6 months in real-world clinics, measuring itch severity and skin lesi…
Sponsor: Galderma R&D • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
New shot aims to stop the maddening itch of prurigo nodularis
Symptom relief Recruiting nowThis study tests an injection called SHR-1819 to see if it can safely reduce the intense itching caused by prurigo nodularis, a chronic skin condition with hard, itchy bumps. About 423 adults will receive either the drug or a placebo, and researchers will track how much their wor…
Phase: PHASE2, PHASE3 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 12:25 UTC
-
New pill could stop the maddening itch of prurigo nodularis
Symptom relief Recruiting nowThis study tests an experimental drug called ICP-332 for people with prurigo nodularis, a skin condition causing many intensely itchy bumps. About 135 adults will receive either the drug or a placebo to see if it reduces itching and clears the bumps over 16 weeks. The goal is to …
Phase: PHASE2 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 12:05 UTC
-
New program aims to reduce shame from chronic illness
Symptom relief Recruiting nowThis study tests a group counseling program called Healing HEARTS to help people with conditions like obesity, skin disease, cancer, HIV, diabetes, or chronic pain deal with internalized stigma. Participants will either join the counseling program or a peer support group. The goa…
Phase: NA • Sponsor: University of Florida • Aim: Symptom relief
Last updated Jun 27, 2026 09:02 UTC
-
Scientists seek skin samples to unlock disease secrets
Knowledge-focused Recruiting nowThis study collects biological samples—like blood, skin biopsies, and swabs—from people with or at risk for skin diseases, as well as healthy volunteers. Researchers will use these samples to study the causes of skin conditions and explore potential treatments. Up to 700 particip…
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Cancer Patients' skin woes under the microscope
Knowledge-focused Recruiting nowThis study looks at how skin conditions related to cancer or cancer treatments affect the well-being of cancer patients and survivors. About 1,025 participants will fill out questionnaires about their skin condition. The goal is to better understand these effects and improve trea…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC